In a patient on lithium with an elevated TSH (~8.7 µIU/mL), low free T4 (~0.42 ng/dL), severe vitamin D deficiency (~12.8 ng/mL), and a subtherapeutic lithium level (~0.4 mEq/L), what management steps should be taken?

Management of Lithium-Induced Hypothyroidism with Concurrent Vitamin D Deficiency

This patient requires immediate initiation of levothyroxine for overt hypothyroidism while continuing lithium therapy, along with high-dose vitamin D supplementation and optimization of the lithium level for therapeutic efficacy.

Primary Issue: Overt Hypothyroidism

With TSH of 8.7 mIU/L and free T4 of 0.42 ng/dL (severely low), this patient has overt hypothyroidism, not subclinical disease. The lithium level of 0.4 mEq/L is subtherapeutic for bipolar disorder management, suggesting the patient may not be achieving adequate psychiatric benefit from current dosing.

Thyroid Management

Start levothyroxine immediately 1. The FDA drug label and clinical guidelines are clear that lithium-induced hypothyroidism should be treated with thyroid hormone replacement while continuing lithium therapy 2. Stopping lithium is not indicated for hypothyroidism 3.

Dosing approach:

• For patients without coronary heart disease and under age 50-60: Start levothyroxine 50-75 µg daily 1
• For patients over 50-60 or with cardiac disease: Start 25-50 µg daily 1
• The severely low T4 (0.42 ng/dL) suggests this patient needs full replacement therapy, approximately 1.6 µg/kg based on ideal body weight 1

Timing and absorption: Instruct the patient to take levothyroxine with water 30-60 minutes before breakfast on an empty stomach 1. Critical caveat: Lithium does not interfere with levothyroxine absorption, so these medications can be taken on the same day without separation 1.

Monitoring schedule:

• Recheck TSH and free T4 in 4-8 weeks after starting levothyroxine 1
• Adjust dose in 12.5-25 µg increments until TSH normalizes 1
• Once stable, monitor TSH every 6 months 1

Secondary Issue: Severe Vitamin D Deficiency

The vitamin D level of 12.8 ng/mL represents severe deficiency. Recent evidence shows vitamin D supplementation significantly reduces TSH levels (SMD = -1.76 mIU/L) and TPO antibodies in hypothyroid patients 4. While vitamin D deficiency is associated with hypothyroidism (OR = 4.06) 4, the relationship is not causative enough to delay levothyroxine treatment.

Vitamin D management:

• Initiate high-dose vitamin D supplementation (typically 50,000 IU weekly for 8-12 weeks, then maintenance dosing)
• Recheck vitamin D levels in 3 months
• This may provide modest additional benefit for thyroid function but is not a substitute for levothyroxine 4, 5

Tertiary Issue: Subtherapeutic Lithium Level

The lithium level of 0.4 mEq/L is below the therapeutic range for bipolar disorder (typically 0.6-1.2 mEq/L for maintenance). This requires psychiatric evaluation to determine if:

• The patient has compliance issues
• The dose needs to be increased for therapeutic benefit
• The patient is on an intentionally low dose for mood stabilization

Important consideration: Lithium causes dose-dependent thyroid dysfunction. Even at low levels (<0.5 mEq/L), mean TSH increases by 0.52 mIU/L; at maintenance levels (0.5-0.8 mEq/L), TSH increases by 1.01 mIU/L 6. However, do not reduce lithium dose to manage hypothyroidism—treat with levothyroxine instead 2, 3.

Monitoring Protocol Going Forward

Thyroid monitoring on lithium:

• TSH should be checked every 6 months during lithium therapy 7
• Most lithium-induced thyroid dysfunction manifests within the first 3 years (91.4% of cases) 7
• The current practice of 3-monthly testing is too frequent and not evidence-based 7

Key pitfall to avoid: Do not stop levothyroxine based on a single normalized TSH value. Some patients show transient TSH fluctuations on lithium that spontaneously resolve, but this patient has overt hypothyroidism requiring sustained treatment 8.

Clinical Context

Lithium-induced hypothyroidism occurs in approximately 20% of patients, with goiter in up to 40% 3, 9. The mechanism involves inhibition of thyroid hormone release and increased thyroid autoimmunity if antibodies are present 3. The FDA label explicitly states that "where hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used" 2.

The treatment hierarchy is:

1. Start levothyroxine for overt hypothyroidism (non-negotiable)
2. Supplement vitamin D for severe deficiency (supportive)
3. Evaluate lithium dosing with psychiatry (for therapeutic efficacy)
4. Continue lithium therapy (do not stop for thyroid issues)